Bone Biologics Corporation's CEO, Jeffrey Frelick, has issued a letter to stockholders providing an update on the company's developments and future outlook. The letter highlights milestones such as the anticipated completion of enrollment in the first-in-human study of NB1 and an interim update. Additionally, the company has extended the shelf life of NB1 from 18 to 24 months in preparation for increased manufacturing scale and is developing a more robust potency assay. Bone Biologics recently raised $5 million through a public offering and expects the current cash position to support planned operations into the second quarter of 2026. The full letter can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012604), on September 04, 2025, and is solely responsible for the information contained therein.